Occuity Ltd.

Compliance Team
Angels Den

Dear User,

You may have heard about the new General Data Protection Regulation (“GDPR”), that comes into effect May 25, 2018.

We would like to ensure you that your personal data is safe with us. Please read the details regarding the processing of your personal data and if you agree with the processing as described below, please click the ‘I agree’ button.

Please be informed that you can withdraw this consent at any time.

1) What data are we talking about?

We are disclosing details regarding the processing of personal data that is collected within our calls and in connection with your use of Angels Den’s platform, Websites and other functionalities of Angels Den, including those saved in cookies files.

2) Who will be the controller of your data?

Angels Den Funding Limited (hereinafter referred to as AD) will be the controller of your data (Angels Den means all entities from the Angels Den capital group, which includes Angels Den Funding Limited with its registered office in London and all entities related to it and dependent on it) and only our Trusted Partners.

3) Why do we want to process your data?

We process this data for the purposes described in our Privacy Policy, including:
- compliance with any legal requirements and obligations,
- ensuring that content from our Website is presented in the most effective manner for you,
- marketing purposes,
- providing you with our services (including the completion and support of immediate activity required to provide you with information and deliver products and/or services that you request and to deliver any contracts entered into with you), or
- as otherwise explained in this privacy policy or by any communication by us.
Where you have explicitly consented to be contacted for such purposes, we use your personal data to provide information on our new and existing products and services.

4) To whom can we transfer data?

In accordance with applicable law, we may transfer your data to entities processing it at our request, e.g. marketing agencies, subcontractors of our services and entities authorized to obtain data under applicable law, e.g. courts or law enforcement agencies - of course only if they submit a request based on an applicable legal basis. Furthermore, we will transfer your data to Trusted Partners outside the European Union – to the USA – under the EU-U.S. Privacy Shield Framework.

5) What are your rights to your data?

You have the right to request access to, correct, delete your personal data. You can also withdraw consent to processing of personal data, raise objections and use other rights granted under GDPR (i.e. right to data portability).

6) Use of cookies

We use cookies to give you the best experience on our Website. This means that we have placed cookies on your device. If you continue without changing your cookie settings, we assume that you consent to our use of cookies on this device. You can change your cookie settings at any time but if you do, you may lose some functionality on our Website. More information can be found in our Privacy Policy.

In connection with the above, I agree to the processing of my personal data by Angels Den and its Trusted Partners. I confirm that I understand that my personal data is being collected as part of my phone calls, use of AD’s online platform, Websites, and other functionalities of AD, including the data saved in cookie files. I also consent to profiling in order to allow Angels Den and its Trusted Partners the provision of better services (including for analytical purposes). Your data will only be processed on a valid lawful basis in accordance with applicable data protection laws. The processing of your personal data for marketing purposes (including statistical analysis) by AD is based on the firm's legitimate interest. The processing for marketing purposes by our Trusted Partners is only possible if we receive your freely given consent. We will also process your personal data to fulfil our contractual obligations to you as contained in AD’s Terms and Conditions of the use of our Website and services. Therefore, this data will be processed on another lawful basis – ‘contract’. We will also process your data to comply with our legal obligations for our Service (such as anti money laundering and know your customer requirements), which is also a valid lawful basis in accordance with applicable data protection laws.

Expressing this consent is voluntary and you can withdraw at any time.

If you have any doubts or questions about the use of your personal data, please do not hesitate to contact me via email. I’m happy to assist.

Compliance Team
Angels Den
cl@angelsden.com

I Agree

Not Now

OCCUITY LTD.

Occuity is unlocking a new era in preventative healthcare by revolutionising the screening & monitoring of diseases such as myopia, diabetes and Alzheimer’s Disease through a simple scan of the eye.

Minimum Target

£ 1,300,000

Minimum investment amount

£ 10,000

Maximum Target

£ 1,999,980

Maximum investment amount

£ 500,000

Investment Opportunity

Founded in 2019 by Dr. Dan Daly, CEO, and Dr. Robin Taylor, CTO, Occuity’s mission is to use the eye as a window to the health of the body. The company’s innovative technology platform, protected by 15 patents, underpins a pipeline of handheld devices that are non-contact, consumable-free and portable. With a PhD in Optics, Dan Daly has spent his career developing optical measurement systems, while Robin Taylor, with a PhD in Biomedical Engineering, has led development of all Occuity’s products. Now with a team of 35 staff spanning R&D, Sales, Marketing, Production, Regulatory, Finance and HR, we are EN13485 certified and manufacture in-house.

THE IDEA

Products & Services

Based on its patented optical technology platform, Occuity is pursuing a strategic, phased pipeline of innovative handheld devices. The first, the PM1 Pachymeter for measuring corneal thickness to support glaucoma diagnosis, is CE marked and has been on the market since late 2024 and is sold via distributors in 19 countries.

The next product, the AX1 Axiometer, due in 2026, addresses the significantly larger myopia management market. Designed to enable global screening and monitoring, it is expected to scale rapidly to 10,000 units annually at an RRP of $10,000. Longer term, Occuity is advancing meters to screen and monitor chronic systemic conditions such as diabetes and Alzheimer’s.

Problem Solved

Today, many medical measurements are invasive or uncomfortable – blood tests involve needles, while in optometry clinicians often need to touch the eye to take a reading. These processes are inconvenient for patients and time-consuming for clinicians.

Occuity’s technology platform solves this by enabling handheld, non-contact devices that deliver quick, pain-free, reliable results. Patients get a far better experience, while clinicians save time and reduce costs. Occuity’s aim is to enable large-scale screening for conditions such as diabetes and Alzheimer’s in a convenient, non-contact way – opening access through high street opticians and pharmacies.

Revenue Model

Occuity’s strategy is to transition from one-off sales to recurring revenues. For our first products, the PM1 Pachymeter and AX1 Axiometer, sales are directly to eye care professionals through our global distribution network. This model is deliberate: optometrists are used to owning their equipment so matching this expectation eases adoption whilst maximising near-term revenues that are critical at this stage.

As we progress to our Oculomics meters, we move to a Device-as-a-Service model, retaining ownership of devices and the global health data they collect. This provides predictable recurring revenues, new monetisation opportunities, and supports a stronger long-term exit valuation.